This morning, Eagle Pharmaceuticals announced that it has entered into an agreement to acquire Arsia Therapeutics. According to Arsia’s website, Arsia’s technology enables the production of high-concentration, low-viscosity biologics that can be delivered to patients by subcutaneous injection, autoinjector pen, or patch pump. Eagle’s press release states that the acquisition…
